Correct Answer: A. ER positive
ER (estrogen receptor) positivity is a well-established good prognostic factor in breast cancer, particularly in BIRADS-5 lesions (highly suspicious for malignancy). ER-positive tumors are typically hormone-responsive, allowing treatment with endocrine therapy (tamoxifen, aromatase inhibitors) which significantly improves disease-free and overall survival. These tumors tend to be lower grade, slower-growing, and have better response to targeted therapy. In the Indian context, ER-positive breast cancers represent approximately 60–70% of all breast malignancies and are associated with longer median survival compared to ER-negative subtypes. The presence of ER positivity allows oncologists to employ hormonal manipulation strategies, which are cost-effective and widely available in Indian cancer centers. ER-positive tumors also correlate with luminal A and luminal B subtypes (by PAM50 classification), which carry better prognosis than triple-negative or HER2-enriched subtypes. This makes ER positivity a critical predictive and prognostic marker that guides both treatment selection and patient counseling regarding long-term outcomes.
Why the other options are wrong
B. p53 positive — p53 positivity (detected by immunohistochemistry) indicates p53 gene mutation or overexpression, which is a poor prognostic marker. p53 mutations are associated with aggressive, high-grade tumors, increased genomic instability, and resistance to chemotherapy and radiation. This is the opposite of a good prognostic factor. NBE may trap students who confuse 'positive' immunostaining with 'positive outcome'—p53 positivity predicts worse prognosis, not better. C. High Ki-67 — High Ki-67 index (>20–30%) is a poor prognostic marker indicating high cellular proliferation and aggressive tumor behavior. Ki-67 is a proliferation marker; elevated levels correlate with shorter disease-free survival, higher grade, and increased likelihood of recurrence. High Ki-67 tumors are typically ER-negative and respond poorly to hormonal therapy. This is a negative prognostic factor, not a positive one. D. BRCA-1 positive — BRCA-1 mutation positivity indicates hereditary breast cancer predisposition, not a prognostic marker of the current tumor. While BRCA-1 mutations increase lifetime breast cancer risk and are associated with earlier onset and higher-grade tumors, BRCA-1 positivity itself is a risk factor, not a prognostic factor for the existing lesion. Patients with BRCA-1 mutations often have triple-negative cancers with worse prognosis. This confuses genetic predisposition with tumor biology.
High-Yield Facts
- ER positivity is the single most important good prognostic factor in breast cancer, enabling endocrine therapy and predicting longer survival.
- p53 mutations (detected as p53 positivity on IHC) are poor prognostic markers associated with aggressive, high-grade, chemotherapy-resistant tumors.
- High Ki-67 index (>20–30%) indicates rapid proliferation and poor prognosis; low Ki-67 (<10%) suggests indolent behavior.
- BRCA-1 mutations are germline predisposition factors, not tumor prognostic markers; they increase risk of triple-negative, aggressive cancers.
- Luminal A (ER+, PR+, HER2−, low Ki-67) has the best prognosis; triple-negative (ER−, PR−, HER2−) has the worst prognosis among breast cancer subtypes.
- In India, ER-positive breast cancers comprise ~60–70% of cases and respond well to tamoxifen and aromatase inhibitors, making ER status critical for treatment planning.
Mnemonics
GOOD Prognostic Factors in Breast Cancer Grade I–II, Outcome (ER+/PR+), Older age, Diploid DNA. ER/PR positivity = hormone-responsive = better prognosis. BAD Prognostic Factors (Remember as OPPOSITES) BRCA mutations, Anaplastic (Grade III), Diploid (aneuploid DNA). Also: p53+, HER2+, high Ki-67, triple-negative.
NBE Trap
NBE may trap students by presenting "positive" immunostaining (p53+, BRCA+) as if positivity = good outcome. In reality, p53 positivity = poor prognosis, and BRCA positivity = genetic risk, not tumor prognosis. Only ER positivity truly means "positive for good outcome."
Clinical Pearl
In Indian breast cancer practice, ER status is the first immunohistochemical marker ordered on all BIRADS-5 lesions. An ER-positive, HER2-negative, low-grade tumor in a 50-year-old woman can be managed with tamoxifen monotherapy or aromatase inhibitors, avoiding chemotherapy toxicity—a significant advantage in resource-limited settings.
_Reference: Bailey & Love Ch. 52 (Breast); Robbins Ch. 24 (Breast Pathology); Harrison Ch. 375 (Breast Cancer)_